LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Arbutus Biopharma Corp

Fermé

3.43 -1.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.4

Max

3.43

Chiffres clés

By Trading Economics

Revenu

-12M

-25M

Ventes

190K

1.8M

BPA

-0.182

Marge bénéficiaire

-1,390.363

Employés

44

EBITDA

-12M

-24M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+44.09% upside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

44M

686M

Ouverture précédente

4.87

Clôture précédente

3.43

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Arbutus Biopharma Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 juin 2025, 18:52 UTC

Résultats

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

20 juin 2025, 16:15 UTC

Acquisitions, Fusions, Rachats

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

20 juin 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

20 juin 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

20 juin 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 juin 2025, 20:13 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 juin 2025, 20:11 UTC

Market Talk

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20 juin 2025, 19:56 UTC

Market Talk

Crude Oil Slips to End Week -- Market Talk

20 juin 2025, 18:35 UTC

Market Talk

Warehouse Clubs Seen Growing Market Share -- Market Talk

20 juin 2025, 18:12 UTC

Market Talk

Gold Slides to Close Shortened Week -- Market Talk

20 juin 2025, 17:56 UTC

Market Talk

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20 juin 2025, 17:50 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 juin 2025, 17:35 UTC

Acquisitions, Fusions, Rachats

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20 juin 2025, 17:30 UTC

Market Talk
Résultats

Adobe's AI Headwinds Seen Fading -- Market Talk

20 juin 2025, 17:03 UTC

Résultats

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20 juin 2025, 16:50 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

20 juin 2025, 16:50 UTC

Market Talk
Résultats

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20 juin 2025, 16:44 UTC

Acquisitions, Fusions, Rachats

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20 juin 2025, 16:40 UTC

Market Talk
Résultats

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

20 juin 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

20 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 juin 2025, 16:17 UTC

Acquisitions, Fusions, Rachats

UniCredit: ULI and UVA Are Expected to Merge in 2026

20 juin 2025, 16:17 UTC

Acquisitions, Fusions, Rachats

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

20 juin 2025, 16:05 UTC

Market Talk

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

20 juin 2025, 15:56 UTC

Market Talk
Résultats

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

20 juin 2025, 15:26 UTC

Market Talk

Natural Gas Slips After Streak of Higher Closes -- Market Talk

20 juin 2025, 15:25 UTC

Acquisitions, Fusions, Rachats

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

20 juin 2025, 15:25 UTC

Acquisitions, Fusions, Rachats

Competition Bureau Says Canadian Natural to Sell 75% Stake in Seiu Lake Natural Gas Plant to North 40 Resources

20 juin 2025, 15:25 UTC

Acquisitions, Fusions, Rachats

Canada Antitrust Regulation Reaches Agreement With Canadian Natural Resources Over Proposed Buy of Schlumberger JV Interest

20 juin 2025, 15:09 UTC

Market Talk

Canadian Retail Sales Show Reversal of Tariff Front-Running -- Market Talk

Comparaison

Variation de prix

Arbutus Biopharma Corp prévision

Objectif de Prix

By TipRanks

44.09% hausse

Prévisions sur 12 Mois

Moyen 5 USD  44.09%

Haut 5 USD

Bas 5 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

3.255 / 3.365Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.